Gerd K Rosenkranz

List of Publications by Year
in descending order

32 papers	**543** citations	687363 **13** h-index	677142 **22** g-index
33 all docs	**33** docs citations	**33** times ranked	**758** citing authors

#	Article	IF	Citations
1	Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. Journal of Neurodevelopmental Disorders, 2016, 8, 1.	3.1	69
2	On the presistence of tumor initiation in two-stage carcinogenesis on mouse skin. Carcinogenesis, 1983, 4, 771-775.	2.8	45
3	Estimands and Their Role in Clinical Trials. Statistics in Biopharmaceutical Research, 2017, 9, 268-271.	0.8	45
4	Bayesian Design of Proof-of-Concept Trials. Therapeutic Innovation and Regulatory Science, 2015, 49, 155-162.	1.6	42
5	Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Scientific Reports, 2018, 8, 16970.	3.3	33
6	Methods for the analysis of multiple endpoints in small populations: A review. Journal of Biopharmaceutical Statistics, 2019, 29, 1-29.	0.8	32
7	On global stability of discrete population models. Mathematical Biosciences, 1983, 64, 227-231.	1.9	30
8	A note on the Hodges–Lehmann estimator. Pharmaceutical Statistics, 2010, 9, 162-167.	1.3	26
9	Subgroup identification in clinical trials via the predicted individual treatment effect. PLoS ONE, 2018, 13, e0205971.	2.5	26
10	The impact of randomization on the analysis of clinical trials. Statistics in Medicine, 2011, 30, 3475-3487.	1.6	20
11	Exploratory subgroup analysis in clinical trials by model selection. Biometrical Journal, 2016, 58, 1217-1228.	1.0	20
12	Analysis of cross-over studies with missing data. Statistical Methods in Medical Research, 2015, 24, 420-433.	1.5	16
13	Bootstrap corrections of treatment effect estimates following selection. Computational Statistics and Data Analysis, 2014, 69, 220-227.	1.2	14
14	Is It Possible to Claim Efficacy if One of Two Trials is Significant While the other Just Shows a Trend?. Drug Information Journal, 2002, 36, 875-879.	0.5	12
15	Applicability and added value of novel methods to improve drug development in rare diseases. Orphanet Journal of Rare Diseases, 2018, 13, 200.	2.7	12
16	Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis. Pharmaceutical Statistics, 2019, 18, 126-139.	1.3	11
17	Missing Data in Noninferiority Trials. Statistics in Biopharmaceutical Research, 2013, 5, 383-393.	0.8	10
18	Remarks on designs enriching for placebo non-responders. Clinical Trials, 2016, 13, 338-343.	1.6	10

#	Article	IF	Citations
19	Growth models with stochastic differential equations. an example from tumor immunology. Mathematical Biosciences, 1985, 75, 175-186.	1.9	9
20	Diffusion approximation of controlled branching processes with random environments. Stochastic Analysis and Applications, 1985, 3, 363-377.	1.5	7
21	Can we reduce the dose of a vaccine?. Contemporary Clinical Trials, 1997, 18, 43-53.	1.9	7
22	Modeling laboratory data from clinical trials. Computational Statistics and Data Analysis, 2009, 53, 812-819.	1.2	7
23	Analysis Sets and Inference in Clinical Trials. Therapeutic Innovation and Regulatory Science, 2013, 47, 455-459.	1.6	7
24	Analysis of Adverse Events in the Presence of Discontinuations. Drug Information Journal, 2006, 40, 79-87.	0.5	6
25	An Approach to Integrated Safety Analyses from Clinical Studies. Drug Information Journal, 2010, 44, 649-657.	0.5	6
26	APL-Programs for the analysis of carcinogenicity experiments. Computer Programs in Biomedicine, 1982, 15, 87-91.	0.7	5
27	Joint Modeling of Outcome, Observation Time, and Missingness. Journal of Biopharmaceutical Statistics, 2011, 21, 252-262.	0.8	5
28	A Note on Ethnic Sensitivity Studies. Journal of Biopharmaceutical Statistics, 2006, 16, 15-23.	0.8	4
29	Estimandsâ€"new statistical principle or the emperor's new clothes?. Pharmaceutical Statistics, 2017, 16, 4-5.	1.3	3
30	Replicability of studies following a dualâ€criterion design. Statistics in Medicine, 2021, 40, 4068-4076.	1.6	2
31	Another view on the analysis of cardiovascular morbidity/mortality trials. Pharmaceutical Statistics, 2011, 10, 196-202.	1.3	1
32	Empirical Bayes estimators in hierarchical models with mixture priors. Journal of Applied Statistics, 2018, 45, 2958-2980.	1.3	1